The company's S-1 lays the groundwork for what is widely expected to be one of the largest initial public offerings of the year, second only to Uber's IPO in May. It's also...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
Trump's tweet comes a day after Apple put out a press release describing the money it spends on U.S.-based suppliers and vendors.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
President Donald Trump held a call on Wednesday with the CEOs of three major U.S. banks, according to people with knowledge of the situation.Marketsread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
Scientists say the smoke plumes, filled with megatons of tiny, harmful particles, could travel to other areas of the world and cause serious respiratory problems for people.Weather & Natural Disastersread more
Some Weight Watchers loyalists applaud Kurbo by WW. But nutritionists worry Kurbo promotes an unhealthy relationship with food during an especially impressionable time.Health and Scienceread more
Benefits from what President Trump called "the biggest reform of all time" to the tax code have dwindled to a faint breeze just 20 months after its enactment, writes John...Politicsread more
Epstein, 66, was found in his cell in Manhattan federal lockup Saturday morning and transferred to a nearby hospital, where he was subsequently pronounced dead.Politicsread more
Air travelers faced delays at U.S. airports on Friday afternoon after a computer issue snarled processing of international arrivals.Airlinesread more
(Adds detail on new CEO and Hudson's replacement at Novartis)
PARIS, June 7 (Reuters) - French pharma giant Sanofi has appointed Paul Hudson as chief executive to replace Olivier Brandicourt, who will retire in September, the company said on Friday.
Hudson, a top executive at Sanofi's Swiss rival Novartis , will take his new job on Sept. 1, the French company said, confirming a Reuters report published on Thursday.
"Hudson has been chosen because of his reputation. He is known as a solid manager and has digital expertise relating to pharmaceuticals," a Sanofi source said on Thursday.
Hudson, 51, has been CEO of the Novartis Pharmaceuticals unit since 2016 after holding positions at Schering Plough and AstraZeneca. He is a member of the Novartis executive committee.
Novartis named Marie-France Tschudin head of its main drugs business to replace Hudson.
Sanofi's management started the search for a new boss months ago to replace 63-year-old Brandicourt.
Brandicourt was hired in 2015 to help to revive the fortunes of France's biggest drugmaker and has been actively reshaping the business.
Under his tenure, the company swapped its animal health unit with Boehringer Ingelheim in exchange for the German company's consumer healthcare operations in a $20 billion deal. It has also sold its European generics arm for 1.9 billion euros ($2.1 billion) to private equity firm Advent International.
New launches such as eczema treatment Dupixent, cost-cutting measures and new priorities in research and development have also enabled Sanofi to return to profit in the second half of last year after a series of disappointing quarters.
Brandicourt's teams, however, failed to land two strategic acquisitions, losing out on buying California-based cancer specialist Medivation to Pfizer in 2016 and failing to acquire Swiss biotech company Actelion, which was bought by Johnson & Johnson in 2017. ($1 = 0.8879 euros)
(Reporting by Matthias Blamont and John Miller Editing by Inti Landauro and David Goodman)